GC Biopharma Corp. (KRX:006280)

Market Cap	1.72T +14.0%
Revenue (ttm)	1.93T +17.7%
Net Income	56.34B
EPS	4,935.38
Shares Out	11.41M
PE Ratio	30.58
Forward PE	37.18
Dividend	1,500.00 (1.01%)
Ex-Dividend Date	Mar 30, 2026

Volume	39,366
Average Volume	58,332
Open	148,900
Previous Close	148,300
Day's Range	148,900 - 151,500
52-Week Range	111,800 - 183,800
Beta	0.85
RSI	44.66
Earnings Date	Mar 19, 2026

About GC Biopharma

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for heredit...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1967
• Employees: 2,042
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 006280

Financial Performance

In 2024, GC Biopharma's revenue was 1.68 trillion, an increase of 3.27% compared to the previous year's 1.63 trillion. Losses were -26.28 billion, -1.32% less than in 2023.